Document is current
Any future updates will be listed below
-
Authors
Hauguel, Teresa
Sharma, Amy
Mastrocola, Emily
Lowry, Susan
Maddur, Mohan S.
Hu, Cheng Hui
Rajput, Swati https://orcid.org/0000-0001-8794-4300
Vitsky, Allison https://orcid.org/0000-0001-6888-789X
Choudhary, Shambhunath
Manickam, Balasubramanian
De Souza, Ivna
Chervona, Yana
Moreno, Raquel Munoz
Abdon, Charisse
Falcao, Larissa
Tompkins, Kristin
Illenberger, Deanne
Smith, Rachel
Meng, Fanyu
Shi, Shuai
Efferen, Kari Sweeney
Markiewicz, Victoria
Umemoto, Cinthia
Hu, Jianfang
Chen, Wei
Scully, Ingrid
Rohde, Cynthia M. https://orcid.org/0009-0007-2627-6581
Anderson, Annaliesa S. https://orcid.org/0000-0002-6413-1718
Suphaphiphat Allen, Pirada
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 19 September 2024
First Online: 7 October 2024
Competing interests
: All authors are current or former employees of Pfizer Inc., and may, as a consequence, be shareholders. Pfizer was involved in the design, analysis, and interpretation of the data in this research study, the writing of this report, and the decision to publish. PSA is an inventor on a patent application related to nucleoside-modified RNA LNP vaccines encoding influenza hemagglutinin.
